Lupin Limited completed acquisition of VISUfarma B.V., a European ophthalmology specialty pharma company, from GHO Capital Partners LLP.
The deal adds over 60 branded ophthalmic products and commercial presence across Italy, UK, Spain, Germany, and France.
VISUfarma generated €53 million in revenue in 2025; Lupin CEO describes the acquisition as 'immediately accretive'.